Research programme: thyroid hormone receptor beta agonists - Viking Therapeutics

Drug Profile

Research programme: thyroid hormone receptor beta agonists - Viking Therapeutics

Alternative Names: MB-10866; TR-beta agonists - Viking; VK 0214

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Metabasis Therapeutics
  • Developer Kennedy Krieger Institute; Viking Therapeutics
  • Class Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adrenoleucodystrophy; Dyslipidaemias; Hyperlipidaemia; Non-alcoholic steatohepatitis

Most Recent Events

  • 21 Mar 2017 Viking Therapeutics has patent protection and pending patent applications for thyroid hormone receptor beta agonists in USA, Australia and Canada
  • 21 Mar 2017 Viking Therapeutics announces intention to submit an IND application for initiation of a phase I trial of VK 0214 for Adrenoleucodystrophy
  • 06 Dec 2016 VK 0214 receives Orphan Drug status for Adrenoleucodystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top